A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.1,002 enrolled

Overview

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,002

Conditions

Major Depressive Disorder

Interventions

Antidepressant + AripiprazoleDRUG

Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women, 18 years or older * Experiencing Major Depressive Disorder with a duration of minimally 8 weeks. * Treatment history of an inadequate response to at least one and no more than four antidepressants

Locations (58)

Outcomes

Primary Outcomes

Safety assessments

Time frame: throughout the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Local Institution

Mesa, Arizona, United States

Local Institution

Peoria, Arizona, United States

Local Institution

Beverly Hills, California, United States

Local Institution

Burbank, California, United States

Local Institution

Encino, California, United States

Local Institution

Garden Grove, California, United States

Local Institution

National City, California, United States

Local Institution

Orange, California, United States

Local Institution

Pasadena, California, United States

Local Institution

Riverside, California, United States

...and 48 more locations